Menu
Recruiting NCT05655156

OrthoPureXT Multiligament PMCF Study

No phase Interventional Multiligament Knee Injuries

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: OrthoPure XT.
Who it may be relevant to
Registry conditions: Multiligament Knee Injuries. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Post Market Clinical Follow-Up of OrthoPureXT for the Treatment of Multiligament Injured Knee: a Case Series

Overview

To monitor residual risks in the post-market phase and to ensure continued clinical evaluation of the device safety and performance to ensure that no new or unexpected risks arise when used during multi-ligament knee reconstructions.

Detailed description

OrthoPureXT is an acellular, sterile, single use, xenograft (porcine) tissue scaffold that is manufactured using a proprietary decellularisation technology that renders the tissue substantially free from cells, leaving the porcine tissue biocompatible, and safe for implantation into the knee.

28 patients in total to be evenly distributed across potential ligament reconstruction treatment options (n=7 per sub-group) and resulting in a statistically relevant number per sub-group considering potential loss to follow up.

Sub-groups of n=7 incurring ligament reconstruction using OrthoPure XT in the following anatomical locations:

* Posterior cruciate ligament (PCL) * Anterior cruciate ligament (ACL) * Posteromedial corner including the medial collateral ligament (MCL) * Posterolateral corner including the lateral collateral ligament (LCL)

Interventions

  • Device OrthoPure XT
    Indication: reconstruction of knee ligaments to restore knee function and stability The following device sizes are available for use in this indication: * Size 5 \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction) * Size 6 \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction) * Size 8 * Primary ACL reconstruction where autograft tissue is not suitable * Revision ACL reconstruction * Multi-ligament reconstr

Primary outcome measures

  • A change from Baseline in IKDC [Time frame: Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)]
Secondary outcome measures (3)
  • A change from Baseline in Lysholm [Time frame: Baseline (30 days prior to surgery); 1, 3 ,6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)]
  • A change from Baseline in KOOS [Time frame: Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)]
  • A change from Baseline in Assessment of Laxity via Physical Examination [Time frame: Baseline (30 days prior to surgery); 1, 3, 6 months after surgery (normal clinical follow-up); 12 and 24 months after surgery (long term follow-up)]

Eligibility criteria

Inclusion criteria

  • Male and female patients aged 18 years old or above.
  • Adults suffering with multiple knee ligament injuries.
  • Ability to communicate meaningfully with investigative staff, competence to give written informed consent; and willingness and ability to comply with entire study procedures including rehabilitation protocol.

Exclusion criteria

  • Those unable to give consent.
  • Those considered as conflicting variables by the investigator. This may include, but is not limited to:
  • Open trauma
  • Neurovascular emergencies
  • Compartment syndrome
  • Life threatening injury
  • Those considered as physical barriers by the investigator, preventing physical or ethical collection of study data. This may include, but is not limited to:
  • Associated fractures that require external fixators
  • Local severe concomitant injuries
  • Injuries to other parts of the body associated with a high level of daily activity/intervention for the patient
  • Those considered as a poor candidate for surgery by the investigator.
  • If female and of child-bearing potential must not have a positive pregnancy test at Visit

1 nor have a stated intention to become pregnant in the next 12 months.

  • Those patients contraindicated for in the IFU, i.e.:
  • Showing signs of infection within 24 hours prior to surgery
  • Patients with known allergy, hypersensitivity, or religious objection to, implanted porcine material
  • Patients unable or unwilling to follow the post-operative care and rehabilitation programme

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United Kingdom · 1 center
  • Royal Stoke University Hospital — Stoke-on-Trent

Identifiers

NCT: NCT05655156 · A03/0028/P01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗